Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The epigenetic silencing of MORT in a large majority of the common human cancers suggests a potential fundamental role in cellular immortalization during human carcinogenesis.
|
26646903 |
2015 |
cervical cancer
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
The results showed that the expression of LncRNA ZNF667-AS1 in cervical cancer was significantly lower than that in normal cervical tissues.
|
29243775 |
2017 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes.
|
28690657 |
2017 |
Breast Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes.
|
28690657 |
2017 |
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes.
|
28690657 |
2017 |
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes.
|
28690657 |
2017 |
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes.
|
28690657 |
2017 |
Malignant tumor of cervix
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results showed that the expression of LncRNA ZNF667-AS1 in cervical cancer was significantly lower than that in normal cervical tissues.
|
29243775 |
2017 |
Cervix carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results showed that the expression of LncRNA ZNF667-AS1 in cervical cancer was significantly lower than that in normal cervical tissues.
|
29243775 |
2017 |
cervical cancer
|
0.320 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Esophageal Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Malignant neoplasm of esophagus
|
0.310 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Bile Duct Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Carcinosarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Uterine Cervical Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Malignant neoplasm of stomach
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Mesothelioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Sarcoma, Epithelioid
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Sarcoma, Spindle Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Bile duct carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Sarcoma
|
0.300 |
Biomarker
|
group |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types.
|
29707199 |
2018 |
cervical cancer
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
MiR-93-3p was found to be highly expressed, while ZNF667-AS1 and PEG3 were poorly expressed in CC.
|
31420931 |
2019 |
Esophageal Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines.
|
31804468 |
2019 |